CPA
TRDA icon

Capital Performance Advisors’s Entrada Therapeutics TRDA Stock Holding History

Capital Performance Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71
Closed -$1.14K – 2475
2024
Q3 		$1.14K Buy
+71
New +$1.12K ﹤0.01% 1845

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Performance Advisors's TRDA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Entrada Therapeutics (TRDA) in Q4 2024, closing a stake of 71 shares — an estimated $1.14K sold.

Capital Performance Advisors first reported a position in TRDA in Q3 2024 and held it in 1 quarter. The position peaked at $1.14K in Q3 2024. 103 funds tracked by Wall St. Rank hold TRDA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Entrada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 71 Entrada Therapeutics shares in Q4 2024, an estimated $1.14K.
  • Capital Performance Advisors first reported a position in Entrada Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Entrada Therapeutics position peaked at $1.14K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.